Gadolinium-associated nephrogenic systemic fibrosis: the need for nephrologists' awareness

被引:0
作者
Canavese, Caterina [1 ,2 ]
Mereu, M. Cristina [3 ]
Aime, Silvio [4 ]
Lazzarich, Elisa [1 ,2 ]
Fenoglio, Roberta [1 ,2 ]
Quaglia, Marco [1 ,2 ]
Stratta, Piero [1 ,2 ]
机构
[1] Amedeo Avogadro Univ, Dept Clin & Expt Med, Maggiore Hosp, I-28100 Novara, Italy
[2] Amedeo Avogadro Univ, IRCAD, Maggiore Hosp, I-28100 Novara, Italy
[3] Dept Nephrol & Dialysis G Brotzu Cagliari, Cagliari, Italy
[4] Univ Turin, Dept Chem IFM, Turin, Italy
关键词
Contrast agent toxicity; Fibrillogenesis; Gadolinium; Nephrogenic fibrosing dermopathy; Nephrogenic systemic fibrosis;
D O I
暂无
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Nephrogenic systemic fibrosis (NSF) / nephrogenic fibrosing dermopathy (NFD) is a recently described disease, occurring only in patients with variable degrees of renal failure (RF) previously exposed to gadolinium-based contrast agents (GBCAs) for magnetic resonance imaging. Public advisories are consistent on some key points including that no cases of NSF/NFD have been reported in patients with normal renal function, and GBCAs may be toxic in patients with RF due to the prolongation of the half-time allowing dissociation and extravasation of highly toxic gadolinium-free ions, potentially linked to the scleroderma-like NSF/NFD, a systemic disabling disease with a mortality rate of up to 30%. The most intriguing feature remains which cofactor might be at play to explain why the disease occurs only in a minority of exposed patients. Therefore, renal dysfunction (substrate) and gadolinium chelates (trigger agent) are necessary but not sufficient. The challenge for nephrologists includes (a) evidence of transmetallation, such as gadolinium deposits in bone, increased urinary zinc excretion, iron-transferrin dissociation or "spurious hypocalcemia" in exposed people; (b) research for uremic cofactors such as increased serum calcium/phosphate, acidosis, use of phosphate-chelating agents able to act as efficient competitor ligands or other drugs; and (c) identification of at-risk patients (with moderate to severe renal dysfunction) and definition of the role of dialysis in removing gadolinium chelates, if any. Nephrologists are called to action to collect and organize information to identify, cofactors for NSF/NFD, and therefore they must be aware of this new pathology, as the eye sees only what the mind knows.
引用
收藏
页码:324 / 336
页数:13
相关论文
共 50 条
  • [31] A follow-up of four cases of nephrogenic systemic fibrosis: is gadolinium the specific trigger?
    Singh, M.
    Davenport, A.
    Clatworthy, I.
    Lewin, J.
    Deroide, F.
    Hubbard, V.
    Rustin, M. H. A.
    BRITISH JOURNAL OF DERMATOLOGY, 2008, 158 (06) : 1358 - 1362
  • [32] Chelation of gadolinium with deferoxamine in a patient with nephrogenic systemic fibrosis
    Leung, Nelson
    Pittelkow, Mark R.
    Lee, Christine U.
    Good, Jonathan A.
    Hanley, Matthew M.
    Moyer, Thomas P.
    CLINICAL KIDNEY JOURNAL, 2009, 2 (03): : 309 - 311
  • [33] The role of gadolinium chelates in the mechanism of nephrogenic systemic fibrosis: A critical update
    Idee, Jean-Marc
    Fretellier, Nathalie
    Robic, Caroline
    Corot, Claire
    CRITICAL REVIEWS IN TOXICOLOGY, 2014, 44 (10) : 895 - 913
  • [34] Gadolinium and nephrogenic systemic fibrosis: have the alarm bells been silenced?
    Tamburrini, O.
    Balducci, A.
    RADIOLOGIA MEDICA, 2012, 117 (01): : 1 - 5
  • [35] Nephrogenic systemic fibrosis and the use of gadolinium-based contrast agents
    Penfield, Jeffrey G.
    PEDIATRIC NEPHROLOGY, 2008, 23 (12) : 2121 - 2129
  • [36] Nephrogenic systemic fibrosis and the use of gadolinium-based contrast agents
    Jeffrey G. Penfield
    Pediatric Nephrology, 2008, 23 : 2121 - 2129
  • [37] Nephrogenic systemic fibrosis in a gadolinium-naive renal transplant recipient
    Anavekar, Namrata S.
    Chong, Alvin H.
    Norris, Richard
    Dowling, John
    Goodman, David
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2008, 49 (01) : 44 - 47
  • [38] Risk factors for developing gadolinium-induced nephrogenic systemic fibrosis
    Peak, Amy S.
    Sheller, Amy
    ANNALS OF PHARMACOTHERAPY, 2007, 41 (09) : 1481 - 1485
  • [39] Nephrogenic systemic fibrosis after exposure to gadolinium in patients with renal failure
    Othersen, Jennifer B.
    Maize, John C.
    Woolson, Robert F.
    Budisavljevic, Milos N.
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2007, 22 (11) : 3179 - 3185
  • [40] Gadolinium - a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?
    Grobner, T
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2006, 21 (04) : 1104 - 1108